Study of Inhaled Iloprost in Pediatric Pulmonary Hypertension (PH) After Surgery

Randomized Double-blind Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension (PH) and Pulmonary Hypertensive Crisis (PHC) After Repair of Congenital Heart Disease (CHD)

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01310751

Enrollment

Registered

2011-03-08

Start date

2011-01-31

Completion date

2013-12-31

Last updated

2015-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension

Brief summary

The aim of this study is to determine whether inhaled iloprost can be used to prevent and treat PH and PHC while in children after operation of CHD

Detailed description

Pulmonary hypertension (PH) is a significant contributor to the postoperative morbidity and mortality of congenital heart disease. Inhaled iloprost has been approved for the treatment of adults with PH, but little is known about the effects in children with PH. Iloprost is a prostacyclin analogue. When applied by inhalation, it selectively dilates pulmonary vessels without side affecting the systemic circulation. There is no RCTs of iloprost have previously been performed in this indication.

Interventions

DRUGiloprost nebuliser solusion

50 ng/kg/min inhalation for 10 minutes, q2h for 2 days

DRUGdistilled water

2 ml per session

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

9 Days to 12 Years

Healthy volunteers

Inclusion criteria

Before corrective procedure for CHD, two of bellow ten criteria should be met 1. Pulse SaO2 smaller than 93% in left-right shunt CHD case (in room air) 2. EKG: right ventricular hypertrophy, right atrial dilatation 3. Chest X-ray: enhanced vascular signs in trans-hilar, loss of blood vessal in bilateral lung fields, pulmonary arterial trunk dilatation, right ventricular enlargement 4. Cardiac echocardiography: fast tricuspid or pulmonary valve regurgitant velocity, ventricular and aortic level bidirectional shunt, or even right-to-left shunt 5. Under-filling of pulmonary capillary, 'pruning' of the peripheral blood vessels 6. Pp/Ps greater than 0.75 7. Qp/Qs smaller than 1.5 8. PVR grater than 9 Wood Unit/m2 9. Rp/Rs graeter than 0.5

Exclusion criteria

After corrective procedure for CHD: 1. Deficient anatomy associated with remained intracardiac shunts and severe artrio-ventricular regurgitation 2. Severe arrhythmia led to low cardiac output 3. PLT smaller than 50,000\*109/L and obvious bleeding

Design outcomes

Primary

Measure	Time frame	Description
The primary end point is a composite variable (incidence rate of any events) consisting of reactive PH, PHC and death requiring additional pharmacological or other support administered within the first 48 hours after receiving study drug.	The pulmonary heamodynamic variable is measured before, after ilkoprost inhalation instantly and 30-min later.	Reactive PH is defined as Pp/Ps greater than 0.5 for more than 30min. End point of observation: in case of Pp/Ps greater than 0.5 for more than 30min or Pp/Ps greater than 1 for any time period, drug inhalation will be immediately stopped and other therapies such as NO inhalation and/or iloprost 80 ng/kg/min inhalation will be resorted to treat pulmonary hypertension.

Secondary

Measure	Time frame
Change from base line of pulmonary heamodynamic measurements: Pp/Ps, PVRI, SVRI	The heamodynamic variable is measured before, after iloprost inhalation instantly and 30-min later.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026